Study Summary
This trial will help build programs to refer people who use drugs to harm reduction services, including syringe services, naloxone overdose prevention, and referral for substance use treatment.
Eligible Conditions
- Opioid Use Disorder
- HIV/AIDS
- Hepatitis C
- Drug Injection
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 14 Secondary · Reporting Duration: 2 years
2 years
Amount of time to travel to the nearest syringe or needle exchange
Number of HCV screenings and referrals
Number of HIV screenings and referrals
Number of locations where participants received most of syringes or needles
Number of participants diagnosed with HCV who have access to HCV care
Number of participants diagnosed with HIV who have access to HIV care
Number of participants that currently have naloxone
Number of participants who have condomless sex (vaginal or anal)
Number of participants with knowledge of PrEP
Substance Use Disorders
Number of times clean syringes and/or equipment obtained from an intervention
Number of times participants let someone else use a cotton, cooker, spoon, or water for rinsing or mixing after they used it
Number of times participants used a cotton, cooker, spoon, or water for rinsing or mixing that they knew was used by somebody else
Number of times participants used a syringe or needle that they knew was used by somebody else
Referrals to the harm reduction organization
Trial Safety
Safety Progress
Trial Design
0 Treatment Group
600 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
Who is running the clinical trial?
National Institute on Drug Abuse (NIDA)NIH
2,250 Previous Clinical Trials
2,028,752 Total Patients Enrolled
University of WashingtonOTHER
1,598 Previous Clinical Trials
1,568,909 Total Patients Enrolled
New York UniversityOTHER
205 Previous Clinical Trials
313,164 Total Patients Enrolled
University of Illinois at ChicagoOTHER
540 Previous Clinical Trials
1,550,877 Total Patients Enrolled
University of ChicagoLead Sponsor
927 Previous Clinical Trials
753,412 Total Patients Enrolled
The Community Action Place, Inc.UNKNOWN
Southern Illinois UniversityOTHER
35 Previous Clinical Trials
4,940 Total Patients Enrolled
Mai Pho, PhDPrincipal InvestigatorUniversity of Chicago
Eligibility Criteria
Age Any Age · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:I haven't injected any drugs in the past 30 days.
Asked if they used any opioids in the past thirty days, fourteen percent of people said yes.
People who are 15 years of age or older are allowed to vote in the United States.
References
- Walters SM, Bolinski RS, Almirol E, Grundy S, Fletcher S, Schneider J, Friedman SR, Ouellet LJ, Ompad DC, Jenkins W, Pho MT. Structural and community changes during COVID-19 and their effects on overdose precursors among rural people who use drugs: a mixed-methods analysis. Addict Sci Clin Pract. 2022 Apr 25;17(1):24. doi: 10.1186/s13722-022-00303-8.
- Rains A, York M, Bolinski R, Ezell J, Ouellet LJ, Jenkins WD, Pho MT. Attitudes toward harm reduction and low-threshold healthcare during the COVID-19 pandemic: qualitative interviews with people who use drugs in rural southern Illinois. Harm Reduct J. 2022 Nov 19;19(1):128. doi: 10.1186/s12954-022-00710-9.
- 2020. "Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04427202.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments